Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 26.50 TWD
Change Today -0.35 / -1.30%
Volume 2.7M
4142 On Other Exchanges
As of 1:38 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

adimmune corp (4142) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/15 - 32.25
52 Week Low
08/25/15 - 14.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ADIMMUNE CORP (4142)

Related News

No related news articles were found.

adimmune corp (4142) Related Businessweek News

No Related Businessweek News Found

adimmune corp (4142) Details

Adimmune Corporation develops, manufactures, and distributes human vaccines in Taiwan. The company’s primary products include AdimFlu-s (AH1N1), Japanese encephalitis vaccine, and tetanus toxoid alum precipitated, as well as influenza vaccine. It also provides fill and finish services; product testing and analysis of quality of vaccines and biological products, as well as other relevant tests; quality assurance courses, comprising introductory courses on GMP-related subjects to schools and industries; and consulting services, such as planning, design, construction, validation, and project management of biological product plant. In addition, the company rents cold storage facilities; and distributes Tuberculin PPD product. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is based in Taichung, Taiwan.

Founded in 1965

adimmune corp (4142) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

adimmune corp (4142) Key Developments

Adimmune and Daiichi Sankyo Signs Agreement to Produce Influenza Vaccine

Adimmune has signed an agreement with Daiichi Sankyo on the manufacture and marketing of an influenza vaccine in Japan. Under the agreement, Adimmune will manufacture flu stock solution for four million doses per year in the first five-year stage, which Daiichi Sankyo will then use to produce the vaccine. Financial details were not disclosed. The co-operation is a positive development for Adimmune building on its recent approval to supply influenza stock solution to the European market as well as Taiwan's biotech industry, which is seeking fresh investment from overseas as it struggles to pull out of a slump and looking to the 2016 election for new, research and development (R&D)-friendly policies.

Adimmune Corporation - Shareholder/Analyst Call

Adimmune Corporation - Shareholder/Analyst Call

Adimmune Corporation, Annual General Meeting, Jun 18, 2015

Adimmune Corporation, Annual General Meeting, Jun 18, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4142:TT 26.50 TWD -0.35

4142 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4142.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4142 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.2x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ADIMMUNE CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at